In Brief: Somerset's Eldepryl
Executive Summary
Somerset's Eldepryl: Capsules will replace the tablet formulation of the Alzheimer's treatment selegiline following May 17 approval of the new form. The capsules will be available within the next two weeks at the same dosage strength and price as the tablets. "The capsule will protect patients from confusing Eldepryl with unsafe counterfeit copies" that have appeared in the U.S., the company says. The capsule will also protect Eldepryl from generic competition; orphan drug exclusivity for Eldepryl expires June 5. Currently filed ANDAs for the generic tablet formulation will not be therapeutically equivalent to the capsule...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth